Cognition Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Cognition Therapeutics, Inc. (CGTX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.97 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2025-03-20
- Cognition Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.98, a 4.81% decline year-over-year.
- Cognition Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.08, a 31.80% decline year-over-year.
- Cognition Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $3.05.
- Cognition Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.97, a 1.99% decline from fiscal 2023.
- Cognition Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.01, a 16.25% decline from fiscal 2022.
- Cognition Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $2.40, a 79.36% decline from fiscal 2021.
- Cognition Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $11.63.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.97 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $1.97 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $1.97 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $1.98 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $2.01 10-K · filed 2024-03-26 | |||
| 2023-09-30 | $2.05 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $2.06 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $2.08 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $2.40 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $2.50 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $2.52 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $3.05 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $11.63 10-K · filed 2022-03-30 | |||
| 2021-09-30 | $2.25 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |